Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria
Open Access
- 30 September 2021
- journal article
- review article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 18 (4), 810-823
- https://doi.org/10.1002/alz.12433
Abstract
Introduction To generalize safety and efficacy findings, it is essential that diverse populations are well represented in Alzheimer's disease (AD) drug trials. In this review, we aimed to investigate participant diversity in disease-modifying AD trials over time, and the frequencies of participant eligibility criteria. Methods A systematic review was performed using Medline, Embase, the Cochrane Library, and Clinicaltrials.gov, identifying 2247 records. Results In the 101 included AD trials, participants were predominantly White (median percentage: 94.7%, interquartile range: 81.0–96.7%); and this percentage showed no significant increase or decrease over time (2001–2019). Eligibility criteria such as exclusion of persons with psychiatric illness (78.2%), cardiovascular disease (71.3%) and cerebrovascular disease (68.3%), obligated caregiver attendance (80.2%), and specific Mini-Mental State Examination scores (90.1%; no significant increase/decrease over time) may have led to a disproportionate exclusion of ethnoracially diverse individuals. Discussion Ethnoracially diverse participants continue to be underrepresented in AD clinical trials. Several recommendations are provided to broaden eligibility criteria.Keywords
Funding Information
- National Science Foundation
- National Institutes of Health (P30 AG066530)
- BrightFocus Foundation (A2021142S)
- Alzheimer's Association (AARGD‐16‐446038)
This publication has 62 references indexed in Scilit:
- The Associations of Clinicians’ Implicit Attitudes About Race With Medical Visit Communication and Patient Ratings of Interpersonal CareAmerican Journal of Public Health, 2012
- Are Patients Whose Study Partners Are Spouses More Likely to be Eligible for Alzheimer’s Disease Clinical TrialsDementia and Geriatric Cognitive Disorders, 2012
- Disease-modifying treatments for Alzheimer’s diseaseTherapeutic Advances in Neurological Disorders, 2011
- A Review of Translations and Adaptations of the Mini-Mental State Examination in Languages Other Than English and SpanishResearch in Gerontological Nursing, 2009
- Utility of the Clinical Dementia Rating in Asian PopulationsClinical Medicine & Research, 2007
- Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?PLoS Medicine, 2005
- The Rowland Universal Dementia Assessment Scale (RUDAS): a multicultural cognitive assessment scaleInternational Psychogeriatrics, 2004
- Development and validation of a geriatric depression screening scale: A preliminary reportJournal of Psychiatric Research, 1983
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960